Evotec SE
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVOTF research report →
Companywww.evotec.com
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.
- CEO
- Christian Wojczewski
- IPO
- 2009
- Employees
- 4,766
- HQ
- Hamburg, DE
Price Chart
Valuation
- Market Cap
- $1.19B
- P/E
- -4.65
- P/S
- 1.21
- P/B
- 1.29
- EV/EBITDA
- -14.43
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 11.47%
- Op Margin
- -13.88%
- Net Margin
- -26.02%
- ROE
- -24.55%
- ROIC
- -7.93%
Growth & Income
- Revenue
- $788.08M · -1.12%
- Net Income
- $-103,478,228 · 47.23%
- EPS
- $-0.58 · 47.75%
- Op Income
- $-140,819,237
- FCF YoY
- 28.13%
Performance & Tape
- 52W High
- $8.58
- 52W Low
- $4.72
- 50D MA
- $5.59
- 200D MA
- $7.24
- Beta
- 1.30
- Avg Volume
- 22
Get TickerSpark's AI analysis on EVOTF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our EVOTF Coverage
We haven't published any research on EVOTF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EVOTF Report →